Journal
SCIENTIFIC REPORTS
Volume 11, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41598-021-99875-9
Keywords
-
Categories
Funding
- Slovenian Research Agency ARRS [P1-0099, J1-2462, J1-1697, N1-0195]
- EU Horizon 2020 under ERC Advanced grant LOGOS
Ask authors/readers for more resources
This study successfully predicted the long-term stability of multiple monoclonal antibody formulations using accelerated stability studies and a first order degradation kinetic model, demonstrating improved robustness, speed, and accuracy in stability prediction. The model was validated through evaluation of stability data from various mAbs, contributing towards the development and refinement of regulatory landscape for extrapolation of biologics.
Long-term stability of monoclonal antibodies to be used as biologics is a key aspect in their development. Therefore, its possible early prediction from accelerated stability studies is of major interest, despite currently being regarded as not sufficiently robust. In this work, using a combination of accelerated stability studies (up to 6 months) and first order degradation kinetic model, we are able to predict the long-term stability (up to 3 years) of multiple monoclonal antibody formulations. More specifically, we can robustly predict the long-term stability behaviour of a protein at the intended storage condition (5 degrees C), based on up to six months of data obtained for multiple quality attributes from different temperatures, usually from intended (5 degrees C), accelerated (25 degrees C) and stress conditions (40 degrees C). We have performed stability studies and evaluated the stability data of several mAbs including IgG1, IgG2, and fusion proteins, and validated our model by overlaying the 95% prediction interval and experimental stability data from up to 36 months. We demonstrated improved robustness, speed and accuracy of kinetic long-term stability prediction as compared to classical linear extrapolation used today, which justifies long-term stability prediction and shelf-life extrapolation for some biologics such as monoclonal antibodies. This work aims to contribute towards further development and refinement of the regulatory landscape that could steer toward allowing extrapolation for biologics during the developmental phase, clinical phase, and also in marketing authorisation applications, as already established today for small molecules.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available